Press release
Leading Companies Reinforce Their Presence in the Upadacitinib Market
Upadacitinib Market
Projected Growth of the Upadacitinib Market by 2030
The upadacitinib market is forecasted to grow rapidly, reaching a value of $2.89 billion by the year 2030. This translates to a compound annual growth rate (CAGR) of 14.0% during the forecast period. Several factors are fueling this expansion, including a rise in clinical approvals for new therapeutic uses, greater emphasis on personalized treatments for autoimmune disorders, broadening oral immunotherapy pipelines, growing investment in inflammation-related research, and an increasing adoption of advanced small molecule drugs. Notable trends influencing this market encompass the growing acceptance of JAK inhibitor therapies, a shift toward oral targeted treatments, increased use of small molecule immunomodulators, a wider range of autoimmune disease indications, and a stronger focus on managing diseases over the long term.
Download a free report of the upadacitinib market report:
https://www.thebusinessresearchcompany.com/report/upadacitinib-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Companies Leading the Upadacitinib Market
The upadacitinib market features numerous influential pharmaceutical firms actively developing and marketing treatments. Prominent players include AbbVie Inc, Pfizer Inc, Eli Lilly and Company, Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Bristol?Myers Squibb Company, Sanofi SA, Takeda Pharmaceutical Company Ltd, Astellas Pharma Inc, AstraZeneca PLC, Gilead Sciences Inc, Teva Pharmaceutical Industries Ltd, Mitsubishi Tanabe Pharma Corporation, Kyowa Hakko Kirin Co Ltd, Galapagos NV, UCB SA, Daiichi Sankyo Company Ltd, Horizon Therapeutics plc, and Regeneron Pharmaceuticals Inc.
Partnerships Accelerating Clinical Development in Upadacitinib
An example of collaborative efforts in this market is the March 2023 partnership between US-based AbbVie Inc. and Lupus Therapeutics, focusing on a Phase 3 clinical program evaluating upadacitinib for systemic lupus erythematosus (SLE). This alliance aims to utilize Lupus Therapeutics' expertise in patient recruitment, site activation, and engagement to speed up the assessment of upadacitinib for this new autoimmune indication. Lupus Therapeutics LLC is known for its role in advancing lupus treatments by managing clinical research and trials efficiently.
View the full upadacitinib market report:
https://www.thebusinessresearchcompany.com/report/upadacitinib-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Emerging Focus on Oral Janus Kinase Inhibitors
A key trend in the upadacitinib market is the development of innovative oral Janus kinase (JAK) inhibitors, which provide promising new options for autoimmune disease management. These small-molecule drugs function by blocking Janus kinase enzymes, thereby reducing immune system overactivation and inflammation. For instance, in April 2023, AbbVie Inc. announced that RINVOQ (upadacitinib) received approval from the European Commission to treat moderately to severely active Crohn's disease. This once-daily oral medication offers patients greater convenience and improved adherence compared to conventional therapies, with a faster onset of action enhancing treatment effectiveness.
Breakdown of Key Segments Driving Market Demand
The upadacitinib market is segmented into several categories to better understand its growth dynamics:
1) By Drug Classes: Janus Kinase Inhibitors, Antirheumatic Agents, Small Molecule Drugs
2) By Application: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease
3) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Further detailing the subcategories:
- Janus Kinase Inhibitors include JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors, and TYK2 Inhibitors
- Antirheumatic Agents cover Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic DMARDs, and Conventional Synthetic DMARDs
- Small Molecule Drugs consist of Oral Small Molecule Drugs and Topical Small Molecule Drugs
This segmentation helps identify the specific areas where upadacitinib is making the most impact and indicates opportunities for future growth within the autoimmune treatment landscape.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leading Companies Reinforce Their Presence in the Upadacitinib Market here
News-ID: 4486786 • Views: …
More Releases from The Business Research Company
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturi …
The peptide therapeutics sector is witnessing significant advancements in the contract active pharmaceutical ingredient (API) manufacturing arena. This market is showing promising growth due to evolving pharmaceutical needs and technological progress, positioning itself for notable expansion in the years ahead. Let's explore the current market size, key growth drivers, major industry players, emerging trends, and segmentation details to better understand this dynamic field.
Projected Market Size and Growth of the Peptide…
Peptide And Oligonucleotide CDMO Market Report Provides Insights Into Market Evo …
The peptide and oligonucleotide CDMO market is experiencing rapid expansion driven by advancements in therapeutic development and manufacturing capabilities. As these complex molecules gain prominence in drug pipelines, the demand for specialized contract development and manufacturing services continues to rise. Let's explore the current market size, key influencers, major players, and emerging trends shaping this dynamic landscape.
Peptide and Oligonucleotide CDMO Market Size and Growth Forecast
The market for peptide and…
Pediatric Drugs Market Analysis Highlights Growth To $352.69 Billion By 2030 At …
The pediatric drugs market has seen remarkable growth in recent years, driven by a range of factors that have improved child healthcare worldwide. With ongoing advancements and expanding healthcare infrastructure, this sector is set for continued rapid expansion in the coming decade. Below is an in-depth overview of the market's size, key drivers, major players, emerging trends, and segmentation.
Strong Growth Trajectory for the Pediatric Drugs Market Size
The pediatric drugs…
Parathyroid Hormone Market Research Reveals Strong 11.9% CAGR Outlook Through 20 …
Understanding the growth trajectory of the parathyroid hormone market reveals promising advancements and expanding opportunities. This sector is witnessing significant development driven by medical innovation and increasing healthcare infrastructure worldwide. Let's explore the current market size, key drivers, major participants, emerging trends, and detailed segmentation to get a comprehensive picture of the parathyroid hormone industry's future.
Parathyroid Hormone Market Size Expansion Until 2030
The market for parathyroid hormone has experienced considerable…
More Releases for Upadacitinib
Giant Cell Arteritis Market: Growth Momentum Across 7MM to 2034 - DelveInsight
The Giant Cell Arteritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Giant Cell Arteritis pipeline products will significantly revolutionize the Giant Cell Arteritis market dynamics.
DelveInsight's "Giant Cell Arteritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Giant Cell Arteritis, historical and forecasted epidemiology as well as the Giant Cell Arteritis market…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Global Upadacitinib Industry Outlook 2025-2029: Market Set to Cross $2.54 Billio …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Upadacitinib Market Size By 2025?
The market valuation for upadacitinib has shown a swift expansion lately, projected to move from a value of $1.32 billion at the end of 2024 to reach $1.5 billion by 2025, reflecting a compound annual growth rate (CAGR) of 13.8%.…
Alopecia Areata Market to Witness Dynamic Shift as AbbVie Reports Positive Topli …
AbbVie is actively pursuing entry into the alopecia areata market. In the second replicate study (Study 1) of its pivotal Phase III UP-AA clinical program (NCT06012240), RINVOQ met the primary endpoint. The results showed that 45.2% of patients receiving 15 mg and 55.0% of those receiving 30 mg of upadacitinib achieved 80% or greater scalp hair coverage by week 24, according to the Severity of Alopecia Tool (SALT) score less…
Global Upadacitinib Market Analysis 2025-2030: Growth Drivers, Challenges, And O …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Upadacitinib Market Size Expected to Be by 2034?
Over recent years, the market size of upadacitinib has experienced a swift expansion. This growth is projected to go up from $1.32 billion in 2024 to $1.51 billion in 2025, boasting a compound annual growth rate (CAGR) of 14.8%.…
Global Upadacitinib Market Projected to Surpass $2.6 Billion by 2029 with 14.5% …
Which drivers are expected to have the greatest impact on the over the upadacitinib market's growth?
The increasing prevalence of autoimmune diseases is expected to stimulate the growth of the upadacitinib market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells. The rise in autoimmune diseases is influenced by genetic factors, environmental triggers, and lifestyle changes. Upadacitinib helps treat autoimmune diseases by targeting…
